What is the most recent earnings date for ACAD stock?
ACADIA PHARMACEUTICALS INC (ACAD) last reported earnings on 2/25/2026.
ACADIA PHARMACEUTICALS INC (ACAD) Earnings History & Surprises
NASDAQ:ACAD • US0042251084
Current stock price
20.75 USD
-0.72 (-3.35%)
At close:
20.7985 USD
+0.05 (+0.23%)
After Hours:
ACAD Earnings overview
Past quarterly earnings results for ACADIA PHARMACEUTICALS INC (ACAD), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.07
- Revenue Estimate
- 289.15M
Last Reported
Most Recent- Release Date
- Feb 25, 2026
- Period
- Q4 / 2025
- EPS Reported
- $1.60
- EPS Surprise
- 1,044.15%
- Revenue Surprise
- -4.84%
Beat Rate
Last 8 Quarters 50%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 1.60 | 0.14 | 1,044.15% | 8,100.00% | 283.989M | 298.42M | -4.84% | 9.39% |
| Q3 2025 | 0.42 | 0.15 | 178.22% | 110.00% | 278.633M | 282M | -1.19% | 11.27% |
| Q2 2025 | 0.16 | 0.14 | 14.46% | -20.00% | 264.566M | 267.05M | -0.93% | 9.34% |
| Q1 2025 | 0.11 | 0.11 | -3.19% | 10.00% | 244.317M | 244.12M | 0.08% | 18.70% |
| Q4 2024 | -0.02 | 0.22 | -109.07% | -107.14% | 259.602M | 283.2M | -8.33% | 12.36% |
| Q3 2024 | 0.20 | 0.14 | 41.97% | 150.00% | 250.401M | 253.79M | -1.34% | 18.28% |
| Q2 2024 | 0.20 | 0.18 | 9.83% | 1,900.00% | 241.963M | 240.37M | 0.66% | 46.44% |
| Q1 2024 | 0.10 | 0.05 | 109.49% | 137.04% | 205.831M | 212.46M | -3.12% | 73.75% |
| Q4 2023 | 0.28 | 0.31 | -9.66% | 207.69% | 231.041M | 228.26M | 1.22% | 69.26% |
| Q3 2023 | -0.40 | -0.43 | 7.97% | -135.29% | 211.699M | 193.28M | 9.53% | 61.97% |
| Q2 2023 | 0.01 | -0.08 | 111.87% | 104.76% | 165.235M | 160.96M | 2.66% | 22.76% |
| Q1 2023 | -0.27 | -0.22 | -23.29% | 18.18% | 118.462M | 122.69M | -3.45% | 2.56% |
| Q4 2022 | -0.26 | -0.25 | -4.94% | 3.70% | 136.5M | 136.75M | -0.18% | 4.36% |
| Q3 2022 | -0.17 | -0.19 | 12.05% | -88.89% | 130.7M | 141.42M | -7.58% | -0.68% |
| Q2 2022 | -0.21 | -0.25 | 16.87% | 22.22% | 134.6M | 133.04M | 1.17% | 16.84% |
| Q1 2022 | -0.33 | -0.61 | 46.18% | 21.43% | 115.5M | 124.35M | -7.12% | 8.35% |
| Q4 2021 | -0.27 | -0.24 | -11.34% | 35.71% | 130.8M | 138.1M | -5.29% | 8.10% |
| Q3 2021 | -0.09 | -0.27 | 66.19% | 83.33% | 131.6M | 130.31M | 0.99% | 9.12% |
| Q2 2021 | -0.27 | -0.31 | 13.13% | - | 115.2M | 127.44M | -9.60% | 4.63% |
| Q1 2021 | -0.42 | -0.54 | 22.52% | 26.32% | 106.6M | 113.87M | -6.38% | 18.31% |
| Q4 2020 | -0.42 | -0.48 | 12.68% | - | 121M | 125.67M | -3.72% | - |
| Q3 2020 | -0.54 | -0.39 | -38.11% | - | 120.6M | 121.2M | -0.50% | - |
| Q2 2020 | -0.27 | -0.45 | 40.17% | - | 110.1M | 105.41M | 4.45% | - |
| Q1 2020 | -0.57 | -0.49 | -16.35% | - | 90.1M | 92.894M | -3.01% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
308.41%
Max EPS beat (4)
1,044.15%
Min EPS beat (4)
-3.19%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-1.72%
Max Revenue beat (4)
0.08%
Min Revenue beat (4)
-4.84%
Analysis
In the last 4 quarters, ACAD has beaten EPS estimates in 3 out of 4 releases
ACAD has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, ACAD has beaten the EPS estimates by 308.4% on average.
In the last 4 quarters, ACAD reported -1.7% below the revenue estimates on average.
Related analysis
ACADIA PHARMACEUTICALS INC / ACAD Earnings FAQ
Did ACADIA PHARMACEUTICALS INC (ACAD) beat earnings estimates last quarter?
ACADIA PHARMACEUTICALS INC (ACAD) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often ACADIA PHARMACEUTICALS INC beats earnings estimates?
In the last 4 quarters, ACADIA PHARMACEUTICALS INC (ACAD) has beaten EPS estimates in 3 out of 4 releases.